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ABSTRACT
Background. Mortality rates following aneurysmal subarachnoid haemorrhage (aSAH) have decreased due to improvements in diag-
noses and the management of complications, as well as early obliteration of the aneurysms. Neurogenic pulmonary oedema (NPO) 
is a clinical syndrome associated with an acute increase in intracranial pressure and a release of catecholamines into the circulation. 
This study investigated independent predictors of unfavourable outcomes (Glasgow Outcome Scores 1, 2 or 3) in patients with aSAH.
Materials and methods. A total of 262 patients with aSAH (162 females) were included in this prospective study. Clinical cha-
racteristics were assessed, and electrocardiographic, serum cardiac and inflammatory biomarker measurements were recorded 
on admission. Outcomes were assessed three months after admission. Univariate and multivariate analyses of these data were 
used to predict unfavourable outcomes.
Results. A total of 156 patients (59.54%) had unfavourable outcomes. Compared to those who had favourable outcomes, patients 
with unfavourable outcomes were significantly older (54.37 ± 10.56 vs. 49.13 ± 10.77 years; p < 0.001) and had more severe aSAHs 
(Hunt and Hess grades ≥ 3: 82.7% vs. 39.6%; p < 0.001). Patients with unfavourable outcomes were more likely to have NPO (10.3% 
vs. 2.8%; p = 0.023), hydrocephalus (34.0% vs. 20.8%; p = 0.02), and aneurysm reruptures (28.2% vs. 3.8%; p < 0.001). Independent 
predictors of an unfavourable outcome included Hunt and Hess grades ≥ 3 (odds ratio [OR], 4.291; 95% confidence interval [CI], 
2.168–8.491; p < 0.001), increased systolic blood pressure on admission (OR, 1.020; 95% CI, 1.002–1.038; p = 0.03), increased heart 
rate (HR) on admission (OR, 1.024; 95% CI, 1.001–1.048; p = 0.04), and aneurysm rerupture (OR, 4.961; 95% CI, 1.461–16.845; p = 0.01).
Conclusions. These findings suggest that aneurysm reruptures, as well as increased blood pressure and HR, are associated with 
unfavourable outcomes in patients with aSAH.
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Introduction
Aneurysmal subarachnoid haemorrhage (aSAH) predo-
minantly affects young adults and results in premature death 
in approximately 40% of patients [11, 30, 38]. Survivors often 
require help with daily living [1]. Neurogenic pulmonary 
oedema (NPO) is a clinical syndrome associated with an 
acute increase in intracranial pressure and a release of cate-
cholamines into the circulation. After traumatic brain injury, 
aSAH is the second most common cause of NPO [2, 6, 28]. 
Patients with aSAH who develop NPO have higher mortality 
rates than those who do not [17, 28, 35]. Hypertension (HTA) 
is the most common comorbid disease, with prevalence esti-
mates exceeding 40% in some studies [18, 20, 41, 42]. No clear 
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association between a premorbid history of HTA and aSAH 
outcome has been established [10, 18–20, 23]. We investiga-
ted the effects of NPO, HTA and other clinical variables on 
outcomes in patients with aSAH.
Materials and methods
Between August 2009 and January 2014, 262 consecutive 
patients who were admitted to the neurosurgery clinic were 
enrolled in the study. The inclusion criteria for the study were 
patients ≥ 18 years of age with an aSAH diagnosis confirmed 
using cerebral computed tomography (CT) scanning and CT 
angiography [24]. If the CT angiogram was negative but the 
suspicion of an aneurysm was high, CT angiography was re-
peated two days later. The time interval between aSAH onset 
and hospital admission was < 96 h. Chest X-rays of patients 
with suspected aSAH were obtained immediately. Patients 
with a history of myocardial infarction, cardiomyopathy or 
congestive heart failure were excluded from the study.
The study protocol was approved by the ethics committee 
of the School of Medicine, University of Belgrade (Belgrade, 
Serbia; no. 440/VI-11); informed consent was obtained from 
each patient or an appropriate designee. The identities of the 
patients were protected. All procedures were performed in 
accordance with relevant institutional guidelines and regu-
lations. After enrolment, demographic and clinical data were 
collected by interviewing patients and their families and by 
reviewing medical records. These data included age, sex and 
risk factors for coronary artery disease. Heart rate (HR) and 
systolic blood pressure (SBP) measurements were recorded 
on admission. Neurological injuries were assessed for severity 
using the Hunt and Hess [12] and Fisher grades [7] recorded 
for each patient on admission. Patients classified as having 
Hunt and Hess grade I or II haemorrhages were admitted to 
the neurosurgery ward, whereas those with haemorrhages 
that were graded III–V were admitted to the neurosurgical 
intensive care unit (NICU).
Clinical management
For each patient, outcomes were determined three months 
after aSAH using the Glasgow Outcome Score (GOS) scale: 
1 = death; 2 = persistent vegetative state; 3 = severe disability, 
conscious but disabled, dependent on others for daily support; 
4 = moderate disability, disabled but independent, can work 
in a sheltered setting; and 5 = good recovery, resumption of 
normal daily living with minor deficits [16]. 
Patients with a GOS of 1, 2 or 3 were classified as having 
unfavourable outcomes, whereas those with a GOS of 4 or 
5 were classified as having favourable outcomes.
Each patient was examined daily for signs of NPO using 
the clinical criteria described by Davison et al. [6], including 
abrupt respiratory distress (tachypnoea, dyspnoea or hypo-
xia [PaO2/FiO2 < 200]), the presence of bilateral crackles on 
auscultation, and the presence of frothy pink tracheal fluid. The 
radiographic criteria used to diagnose NPO included sharply 
defined bilateral pulmonary markings accompanied by blur-
ring or haziness of the perivascular outlines and a loss of hilar 
shadow demarcation [28]. All chest X-rays were interpreted by 
board-certified radiologists who were blinded to the patients’ 
clinical symptoms. The spontaneous resolution of pulmonary 
infiltrates occurred within 48 h. Patients who fulfilled all of 
these criteria were diagnosed with NPO. Arterial blood gas 
analyses were used to determine the type of respiratory support 
necessary. If inotropic or vasopressor support was necessary, 
we recorded when this was initiated. All NICU patients were 
monitored continuously using electrocardiography (ECG) 
and by recording noninvasive blood pressure measurements 
in accordance with standard clinical practice. Central venous 
catheters, but not pulmonary artery catheters, were used [11]. 
All procedures were performed in accordance with the relevant 
aSAH treatment guidelines and recommendations [4, 37, 38].
Electrocardiographic, serum cardiac and 
inflammatory biomarkers
Twelve-channel ECG was used on the day of each patient’s 
enrolment to measure ST–T changes (e.g. ST depression 
or elevation, negative, biphasic or flattened T waves), the 
corrected Q–T wave (QTc) interval, rhythm disturbances 
and ventricular premature complexes. All electrocardio-
graphic measurements were interpreted by board-certified 
cardiologists.
The following biomarkers for cardiac injury and inflam-
mation were measured: creatine phosphokinase (CPK), CPK 
muscle/brain isoenzyme (CPK-MB), cardiac troponin I (TnI), 
and C-reactive protein (CRP). Total serum CPK and CPK-MB 
isoenzyme activities were measured using standard spectrop-
hotometry. Serum TnI levels were measured using a chemilu-
minescence enzyme immunoassay. CRP was measured using 
turbidimetry. Biomarker levels were classified as elevated if 
they exceeded the following reference levels: CPK, 150 IU/L 
for women and 200 IU/L for men; CPK-MB, 24 IU/L; TnI, 
0.04 ng/mL; and CRP, 5 mg/L. The time interval between the 
onset of aSAH symptoms and biomarker measurements was 
less than 96 h for every patient.
Neurological assessments
Every patient was neurologically assessed and clinical 
signs of hydrocephalus, delayed cerebral ischaemia (DCI) 
and aneurysm reruptures were recorded. CT scans were also 
performed if there were signs of neurological deterioration. 
The term ‘vasospasm’ is used for narrowing of the large ce-
rebral arteries and DCI caused by cerebral infarction and/or 
neurological deterioration. The criteria for aneurysm rerupture 
were new clinical signs of neurological deterioration together 
with signs of new bleeding on a CT scan.
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We only used clinical and radiological criteria (CT scans) 
to diagnose DCI and did not prove that this was due to vaso-
spasm. Therefore, this data was not included in our analyses.
Statistical analyses
A total of 262 patients were dichotomised based on their 
three-month outcomes (unfavourable, GOS = 1–3 or favour-
able, GOS = 4–5). Categorical variables were expressed as 
frequencies and percentages, whereas continuous variables 
were expressed as means ± standard deviations. The Kol-
mogorov-Smirnov test was used to confirm that the data was 
normally distributed. For the unfavourable versus favourable 
group comparisons, chi-square and Fisher’s exact tests were 
used for categorical variables, whereas unpaired t-tests and 
Mann-Whitney U tests were used for continuous variables. 
Univariate and multivariate logistic regression analyses 
were used to identify variables that predicted unfavourable 
outcomes. The data was analysed using SPSS software (ver. 
22.0; IBM Corp., Armonk, NY, USA); a p-value < 0.05 was 
considered statistically significant.
Results
This study included 262 patients of whom 59.54% (156 pa-
tients) had unfavourable outcomes. A total of 368 patients with 
aSAH were assessed, and 106 patients (28.8%) were excluded. 
The reasons for exclusion were: 54 patients were admitted to 
hospital more than 96 h after aSAH onset, and 21, 16 and 
15 patients had a history of myocardial infarction, cardiomy-
opathy, and congestive heart failure, respectively.
The mean ages of the 156 patients with unfavourable out-
comes and the 106 patients with favourable outcomes were 
54.37 and 49.13 years, respectively (p < 0.001; Tab. 1). A total 
of 63.5% of the patients with NPO were women, whereas 
60.1% of the patients who did not have NPO were women 
(p = 0.04). A history of HTA was more common among pa-
tients with NPO (p = 0.001). There were significantly more 
patients with Hunt and Hess grades ≥ 3 among those with 
unfavourable outcomes than among those with favourable out-
comes (p < 0.001). A comparison of radiological characteristics 
revealed a significant increase in the incidence of NPO among 
patients with Fisher grades > 2 (p < 0.001). In addition, the 
mean peak SBP and HR were significantly increased in patients 
with unfavourable outcomes (p < 0.001 and 0.007, respectively).
Electrocardiographic measurements showed that there 
were no significant differences in the ST–T or QTc interval 
between patients with favourable and unfavourable outcomes. 
It was not clear whether patients with unfavourable outcomes 
had more severe cardiac damage than patients with favour-
able outcomes. The mean CPK-MB levels were significantly 
increased in patients with unfavourable compared to those 
with favourable outcomes (15.3 ± 7.3 vs. 13.5 ± 6.6 IU/L; 
p = 0.04), but the mean TnI (0.246 ± 0.870 vs. 0.219 ± 0.822 ng/mL; 
p = NS) and CPK (143.8 ± 103.2 vs. 132.6 ± 93.2 IU/L; p = NS) 
levels were not. However, unfavourable outcomes were sig-
nificantly more common among patients with elevated CPK 
levels (33.3% vs. 20.8%; p = 0.03). Mean CRP levels were not 
significantly increased in patients with unfavourable com-
pared to those with favourable outcomes (6.56 ± 6.40 vs. 5.52 
± 4.48 mg/L; p = NS).
The neurological assessments showed that aneurysm re-
ruptures and hydrocephalus were significantly more common 
among patients with unfavourable compared to those with 
favourable outcomes (p = 0.02 and < 0.001, respectively). 
Patients with favourable outcomes also had a significantly 
increased frequency of secured aneurysms (p < 0.001).
The GOSs of patients with aSAH showed that 36 patients 
(13.7%) recovered well, 32 (12.2%) had moderate disability, 
83 (31.7%) had severe disability, 71 (27.1%) were in a persistent 
vegetative state, and 36 patients (13.7%) died. After univariate 
logistic regression analysis and adjustment using multivariate 
logistic regression (Tab. 2), we identified the following inde-
pendent predictors of unfavourable outcomes: Hunt and Hess 
grades ≥ 3 (odds ratio [OR], 4.291 per quintile; 95% confidence 
interval [CI], 2.168–8.491; p < 0.001), aneurysm reruptures 
(OR, 4.961; 95% CI, 1.461–16.845; p = 0.01), increased SBP 
(OR, 1.020; 95% CI, 1.002–1.038; p = 0.03), increased HR 
(OR, 1.024; 95% CI, 1.001–1.048; p = 0.04), and unsecured 
aneurysms (OR, 9.377; 95% CI, 1.138–77.244; p = 0.04).
Discussion
A comparison of demographic characteristics revealed 
that patients with unfavourable outcomes were significantly 
more likely to have had a severe haemorrhage (Hunt and Hess 
grades III–V) than patients with favourable outcomes (Tab. 1) 
[17, 28, 35]. In our cohort of 262 patients with aSAH, the inci-
dence of unfavourable outcomes was 59.5%. In a multicentre 
study performed by Galea et al. [9], 28.6% of the patients had 
unfavourable outcomes. The difference between these studies 
may be due to patients in the multicentre study having a better 
neurological status on admission. In the multicentre study, the 
haemorrhage severity scores of almost 70% of patients were 
World Federation of Neurosurgeons grade I or II on admis-
sion, whereas in our study 35% of patients had a Hunt and 
Hess severity grade of I or II. All patients with unfavourable 
outcomes had severe bleeding (Fisher grades III and IV) that 
was radiologically visible [47].
In contrast to previous studies, we did not find that a rup-
tured aneurysm in the posterior circulation was a risk factor 
for unfavourable outcomes [14, 28, 31]. If patients in this 
category died before they reached hospital, this may explain 
why we did not observe a significant effect. Previous studies 
have also described electrocardiographic abnormalities and 
myocardial enzyme release in patients with aSAH [3, 29, 39], 
but the effect of cardiac dysfunction on aSAH outcome remains 
unclear. Serum cardiac biomarkers have been used to predict 
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Table 1. Comparison of variables between aSAH patients with unfavourable and favourable outcomes
Pts with unfavourable outcome 
N = 156
Pts with favourable outcome 
N = 106
Pb
Age (mean ± SD), y 54.37 ± 10.56 49.13 ± 10.77 < 0.001a
Female sex, n (%) 99 (63.5) 63 (59.4) NS
Clinical characteristics
Hunt and Hess ≥ 3, n (%) 129 (82.7) 42 (39.6) < 0.001a
SBP (mean ± SD), mmHg 156.57 ± 23.35 137.36 ± 21.28 < 0.001a
HR (mean ± SD), min-1 84.29 ± 16.96 78.92 ± 14.03 0.007a
Admission on day of aSAH attack, n (%) 72 (55.8) 57 (53.8) NS
NPO, n (%) 16 (10.3) 3 (2.8) 0.02a
Risk factors for CAD, n (%)
History of hypertension 72 (46.2) 28 (26.4) 0.001a
History of smoking 31 (19.9) 35 (33.0) 0.02a
History of diabetes 27 (17.3) 19 (17.9) NS
History of hyperlipidemia 44 (28.2) 33 (31.1) NS
Family history of CAD 42 (26.9) 26 (24.5) NS
Radiological characteristics
Fisher > 2, n (%) 123 (78.8) 47 (44.3) < 0.001a
Anterior circulation aneurysm location, n (%) 138 (88.5) 95 (89.6) NS
Multiple aneurysms, n (%) 14 (9.0) 14 (13.2) NS
ECG  characteristics
ST-T changes, n (%) 41 (26.3) 23 (21.7) NS
ST depression, n (%) 22 (14.1) 7 (6.6) NS
ST elevation, n (%) 19 (12.2) 11 (10.4) NS
Negative T waves, n (%) 14 (9.0) 10 (9.4) NS
Prolonged QTc interval, n (%) 30 (19.2) 11 (10.4) NS
Ventricular premature complexes, n (%) 14 (9.0) 10 (9.4)      NS
Neurological characteristics
Secured c aneurysm, n (%) 109 (69.9) 105 (99.1) < 0.001a
Hydrocephalus, n (%) 53 (34.0) 22 (20.8) 0.02a
Rerupture, n (%) 44 (28.2) 4 (3.8) < 0.001a
Seizures, n (%) 30 (19.2) 23 (21.7) NS
Biohumoral characteristics
Troponin I, (mean ± SD), ng/mL, median (IQR) 0.246 ± 0.870 
0.021 (0.010–0.063)
0.219 ± 0.822 
0.020 (0.011–0.054)
NS
Elevated troponin I, n (%) 50 (32.1) 32 (30.2) NS
CPK (mean ± SD), IU/L, 
median (IQR)
143.8 ± 103.2 
112.0 (68.5–213.0)
132.6 ± 93.2 
103.5 (76.5–164.3)
NS
Elevated CPK, n (%) 52 (33.3) 22 (20.8) 0.03a
CPK-MB (mean ± SD), IU/L,  
median (IQR)
15.3 ± 7.3 
14.0 (10.0–2.0)
13.5 ± 6.6 
12.0 (8.0–17.0)
0.04a
Elevated CPK-MB, n (%) 18 (11.5) 9 (8.5) NS
C-reactive protein (mean ± SD), mg/L 
median (IQR)
6.56 ± 6.40 
4.95 (2.83–8.85)
5.52 ± 4.48 
4.55 (2.88–6.95)
NS
Elevated C-reactive protein, n (%) 76 (48.7) 45 (42.5) NS
aSAH — aneurysmal subarachnoid haemorrhage; NPO — neurogenic pulmonary oedema; SBP — systolic blood pressure; HR — heart rate; CAD — coronary artery disease; ECG —electrocardiography; SD — 
standard deviation; IQR — interquartile range; CPK — creatine phosphokinase; CPK-MB — creatine phosphokinase MB isoenzyme
aStatistically significant
bAccording to chi-square, Student’s t-test or Mann-Whitney U test where appropriate
cAll of 214 pts with secured aneurysm had aneurysm clipped, except three of them (all with unfavourable outcomes) whose aneurysms were coiled
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Table 2. Multivariate logistic regression analysis to identify variables 
predictive of unfavourable outcome associated with aSAH
Multivariate
Predictor OR 95% CI P
Age, years 1.030 0.999–1.063 NS
Female sex 1.750 0.863–3.548 NS
Hunt and Hess grade ≥ 3 4.291 2.168–8.491 < 0.00a
History of HTA 0.749 0.349–1.606 NS
History of smoking 1.852 0.878–3.908 NS
NPO 2.104 0.433–10.215 NS
SBP 1.020 1.002–1.038 0.03a
HR 1.024 1.001–1.048 0.04a
Hydrocephalus 1.607 0.766–3.371 NS
Rerupture 4.961 1.461–16.845 0.01a
Unsecured aneurysm 9.377 1.138–77.244 0.04a
Prolonged QTc 0.757 0.266–2.154 NS
CPK-MB (IU/L) 1.006 0.954–1.061 NS
CI — confidence interval; OR — odds ratio; aSAH — aneurysmal subarachnoid haemorrhage; 
HTA — hypertension; NPO — neurogenic pulmonary oedema; SBP — systolic blood pressure; 
HR — heart rate; CPK-MB — creatine phosphokinase MB isoenzyme
aStatistically significant
negative outcomes [21, 22, 25, 43, 44, 46]. In our study, only 
mean CPK-MB levels were significantly increased in patients 
with unfavourable outcomes. Univariate logistic regression 
analysis revealed that increased levels of CPK-MB could 
predict unfavourable outcomes. A meta-analysis by Zhang et 
al. [46] showed that an increase in TnI was associated with an 
increased risk of poor outcome (OR 1.85; 95% CI 1.49–2.30).
In our study, electrocardiographic abnormalities did not 
occur more frequently in patients with unfavourable outcomes. 
A prolonged QTc interval did predict unfavourable outcomes 
in the univariate logistic regression analysis. However, neither 
of these variables was an independent predictor of unfavoura-
ble outcomes [13]. In many studies, NPO is associated with un-
favourable outcomes [17, 28, 36]. However, in our study, NPO 
was not an independent predictor of unfavourable outcomes.
Multivariate logistic regression analysis revealed that Hunt 
and Hess grades, aneurysm reruptures, increased SBP and HR and 
unsecured aneurysms were independent predictors of unfavoura-
ble outcomes in patients with aSAH. Previous studies have shown 
that the only consistent and independent predictors of negative 
outcomes in aSAH patients are poor haemorrhage severity grades, 
older age, aneurysm reruptures, and DCI [27, 32, 33, 45].
Neurological status on admission to hospital reflects 
the severity of a brain injury at the time of rupture. This is 
the single most important predictor of outcomes in patients 
with aSAH [38, 45]. Jaja et al. [15] demonstrated that each 
one-point increase in neurological grade resulted in an ap-
proximately two-fold increase in the risk of a poor outcome 
at three months.
Many studies have shown that aneurysm rerupture is 
a strong predictor of outcomes in patients with aSAH [40]. 
Early treatment of a ruptured aneurysm is particularly im-
portant to reduce rebleeding [9]. In addition, an unsecured 
aneurysm, with or without rebleeding, is a predictor of poor 
outcomes in patients with aSAH because more aggressive 
measures (e.g. HTA and haemodilution therapy) can be used 
to prevent vasospasm in patients with a secured aneurysm.
In patients with aSAH, an association between HTA and 
outcomes has been supported by some studies [6, 18, 19, 34, 
42] and questioned by others [6, 10, 20, 23, 26]. De Marchis 
et al. [5] found that patients with premorbid HTA had more 
severe initial bleeding and an increased risk of mortality while 
in hospital. Our study found that increased SBP, but not pre-
morbid HTA, was a predictor of negative outcomes.
Zheng et al. [48] also showed that good control of pre-
morbid HTA had a favourable effect on outcomes in patients 
with aSAH. Patients with uncontrolled HTA had more severe 
aSAH and haemorrhage grades than patients with well-con-
trolled HTA. In addition, the patients with uncontrolled 
HTA included more frequent cases of aneurysm rebleeding, 
hydrocephalus and cerebral vasospasm, even after adjustment 
for age and poor Hunt and Hess grade. 
However, we found that a history of premorbid HTA was 
not a predictor of unfavourable outcomes in aSAH patients. 
Increased HR on admission was an independent predictor of 
negative outcomes. Schmidt et al. [36] showed that a prolonged 
elevated HR was associated with major adverse cardiopulmo-
nary events and poor outcomes in aSAH patients.
This study has some limitations. Firstly, different time 
intervals between the onset of aSAH and hospital ad-
mission may have influenced our results. Secondly, we 
excluded patients with a history of myocardial infarction, 
congestive heart failure and cardiomyopathy to investigate 
the incidence of NPO in patients with aSAH. This may 
also have influenced our results. Finally, we only recorded 
measurements once and this was within 96 h of aSAH onset. 
In total, 50.8% of these measurements were recorded after 
the initiation of aSAH therapy. Despite these limitations, 
this is the only study to have investigated the spectrum of 
clinical, radiological and biochemical variables that may be 
used to predict negative outcomes in patients with aSAH. 
The influence of aSAH treatment on these results should be 
assessed in more detail.
Conclusions
In patients with aSAH, the predictors of unfavourable 
outcomes include a high Hunt and Hess grade, aneurysm 
rerupture, and an unsecured aneurysm, as well as increased 
SBP or HR. NPO and premorbid HTA are not independent 
predictors of unfavourable outcomes.
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